Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BWC2094
- Development stage
- Preclinical
- Lead developer
- Bugworks Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BWC2094 is a small molecule dual antagonist of the adenosine A2A and A2B receptors (A2AR/A2BR) currently in preclinical development by Bugworks Research. Described as a "triple effector" agent, it is designed to target the adenosine axis within the tumor microenvironment to overcome immunosuppression. By blocking both A2AR and A2BR, BWC2094 aims to enhance the activity of T-cells and NK-cells while potentially exerting direct effects on tumor growth and metastasis. The program is focused on treating various solid tumors, including colorectal cancer, non-small cell lung cancer, triple-negative breast cancer, and pancreatic cancer.
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)
Beyond the preview
Go deeper on BWC2094.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BWC2094.